Antonio Passaro, MD, PhD is a medical oncologist at the European Institute of Oncology in Milan, Italy, a major Italian Cancer Center. He received the PhD in molecular medicine with focus on lung cancer. Dr Passaro’s research activities focus on lung cancer. His major interest is in predictive and prognostic factors in patients candidate to receive target agents, in particular EGFR TKI, and immunotherapy, as well as the sequence of therapy in lung cancer. He has involved as Principal Investigator or Sub-Investigator in many sponsored and academic trials across a broad range of novel therapies. He is currently a member of ESMO faculty for Lung and other Thoracic Tumours, member of the ESMO-MCBS working group and he is currently a member of the Italian Committee for Guidelines in Lung Cancer by AIOM (Associazione Italiana di Oncologia Medica).
Dr Passaro published many papers in international peer-reviewed journals and several abstract at international meetings, including many on the use of EGFR TKIs for the treatment of common and uncommon EGFR mutations in NSCLC.
Date of preparation: January 2021